These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32204371)

  • 1. Mass Spectrometry Advances and Perspectives for the Characterization of Emerging Adoptive Cell Therapies.
    Lombard-Banek C; Schiel JE
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32204371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What CAR Will Win the CD19 Race?
    Quintás-Cardama A
    Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation.
    Pantin J; Battiwalla M
    Br J Haematol; 2020 Sep; 190(6):851-853. PubMed ID: 32358811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
    Papadouli I; Mueller-Berghaus J; Beuneu C; Ali S; Hofner B; Petavy F; Tzogani K; Miermont A; Norga K; Kholmanskikh O; Leest T; Schuessler-Lenz M; Salmonson T; Gisselbrecht C; Garcia JL; Pignatti F
    Oncologist; 2020 Oct; 25(10):894-902. PubMed ID: 32339368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
    Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective.
    Lin X; Lee S; Sharma P; George B; Scott J
    J Clin Oncol; 2022 Oct; 40(30):3501-3509. PubMed ID: 35613410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
    Perica K; Curran KJ; Brentjens RJ; Giralt SA
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1135-1141. PubMed ID: 29499327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
    Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
    Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cell product performance in haematological malignancies before and after marketing authorisation.
    Elsallab M; Levine BL; Wayne AS; Abou-El-Enein M
    Lancet Oncol; 2020 Feb; 21(2):e104-e116. PubMed ID: 32007196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
    Kiani J; Naderi M; Torabi-Rahvar M; Ranjbar A; Aghayan HR; Janzamin E; Ahmadbeigi N
    Arch Iran Med; 2019 Jan; 22(1):7-10. PubMed ID: 30821155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
    Nair R; Neelapu SS
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.
    Dudley CV; Baer B; Simons RM
    Semin Oncol Nurs; 2019 Oct; 35(5):150930. PubMed ID: 31561845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
    Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies.
    Zurko JC; Xu H; Chaney K; Schneider D; Szabo A; Hari P; Johnson BD; Shah NN
    Cytotherapy; 2022 Aug; 24(8):767-773. PubMed ID: 35597752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
    Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
    Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.
    Feins S; Kong W; Williams EF; Milone MC; Fraietta JA
    Am J Hematol; 2019 May; 94(S1):S3-S9. PubMed ID: 30680780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.